VALUATION REPORT

OF

ASSTON PHARMACEUTICALS LIMITED
CIN: U24304MH2019PLC324187

As on: 1st July, 2026
(Relevant Date)

Date of Issue: 2nd July, 2026

Place: Ludhiana

Prepared by:
Amninder Kaur
Registered Valuer – Securities or Financial Assets
IBBI Regd. No.: IBBI/RV/03/2021/14025
Address: 69, Phase 3, SKS Nagar, Ludhiana-141013 (Punjab)
Contact: +91 89688 83634
Email: cs.kauramninder@gmail.com

Date: 02.07.2026

To,

The Board of Directors,
Asston Pharmaceuticals Limited,
CIN: U24304MH2019PLC324187
4th Floor Office No A-431 Balaji Bhavan,
Plot No 42a Sector-11 CBD Belapur,
Navi Mumbai, Thane, Maharashtra, 400614, India

Ref: Valuation Report of Asston Pharmaceuticals Limited, ("Company") as on July 01, 2026 for determining Floor Price of Equity Shares.

In reference to the valuation of equity shares (the "Shares") of, **M/s Asston Pharmaceuticals Limited** (the "Company"), Ms. Amninder Kaur, Registered Valuer-Securities and Financial Assets having registration no. IBBI/RV/03/2021/14025 (the "Valuer") has been appointed by the Company to arrive at the Floor Price for Preferential Allotment of Equity Shares.

This cover letter is intended to provide you with an overview of the purpose and scope of our analysis and our conclusion. Please refer to the attached report and presentation of the analysis performed in connection with this engagement.

Purpose and Scope

Based on our discussion with the Management, we understand that the purpose of this valuation engagement is to arrive at the Floor Price of Equity Shares of the Company listed on Recognized Stock Exchange for the purpose of further issue of shares by way of Preferential Allotment in conformity with Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR), as amended from time to time.

The report has been prepared exclusively for specified purpose as mentioned above and hence should not be used for any other purpose, without obtaining the prior written consent from the valuer. In the event, the Company or its management or its representatives intend to extend the use of this report beyond the purples mentioned, with or without consent, we will not accept any responsibility to any party who uses this report or to whom this report may be shown or who may acquire the report. This opinion should not be considered, in whole or in part, as an investment advice by anyone.

Summary of Findings

Based on the assumptions and limiting conditions as described in the report I conclude that:

Fair Value as per Reg 166A of ICDR Regulations			
Method of Valuation	**Value of per Equity Share (in Rs.)**	**Weightage**	**Weighted Value (in Rs.)**
Asset Approach (A)	45.65	10%	4.54

PECV (B)	125.36	40%	50.15
Weighted Average Price (C)	80.25	50%	40.13
Fair Value of Equity Share (A+B+C)			94.84
Fair Value as per Reg. 166A (D) (Rounded Off)			**Rs. 95**

Fair Value as per Reg 164 of ICDR Regulations	**Source : BSE Data**
90 trading days' Value	Rs. 73,258,360
90 trading days' Volume	969,000
10 trading days' Value	Rs. 24,635,150
10 trading days' Volume	353,000
90 trading days' Volume Weighted Average Price (E)	Rs. 75.60
10 trading days' Volume Weighted Average Price (F)	Rs. 69.79
Value as per Reg. 164 (Higher of (E) or (F) above)	Rs. 75.60
Fair Value as per Reg 164 (G) (Rounded Off)	**Rs. 76**

	Per Share Value (In Rs.)
Fair Value of Equity Shares as per Regulation 166A of ICDR Regulations - (D)	95
Fair Value of Equity Shares as per Regulation 164 of ICDR Regulations - (G)	76
Minimum Price at which shares can be issued (Higher of D or G above)	**Rs. 95**

A detailed report along with the annexure for valuation under Regulation 166 A and Regulation 164 of ICDR is appended herewith.

Registered Valuer SFA
Amninder Kaur
Regd. No. IBBI/RV/03/2021/14025

(Amninder Kaur)
Registered Valuer-SFA
IBBI Regd No.: IBBI/RV/03/2021/14025
Place: Ludhiana

Table of Contents

Registered Valuer SFA ★ Amninder Kaur Regd. No. IBBI/RV/03/2021/...

1. Company Overview

A. Master Data

1.	Subject Company's Name	:	ASSTON PHARMACEUTICALS LIMITED
2.	CIN	:	U24304MH2019PLC324187
3.	Constitution	:	Public Limited Company
4.	Registered Office	:	4th Floor, Office No. A-431, Balaji Bhavan, Plot No. 42A, Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, India, 400614
5.	Address other than R/o where all or any books of accounts and papers are maintained	:	
6.	Email	:	compliance@asstonpharmaceuticals.com
7.	Year of Incorporation	:	2019
8.	Authorized Capital (IN INR)	:	11,00,00,000
9.	Paid Up Capital (IN INR)	:	8,51,23,600
10.	Purpose	:	Determination of Fair Value of Equity Shares for the purpose of Preferential Allotment.

2. Engagement Overview

a) Purpose of Valuation and Appointing Authority:

The purpose of this valuation engagement is to arrive at the Floor Price of the Equity Shares of the Company for the purpose of further issue of shares by way of Preferential Allotment in accordance with the provisions of regulation 166A of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR) read with regulation 164 of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR), as amended from time to time.

Appointing Authority: Board of Directors of M/s Asston Pharmaceuticals Limited vide Board Resolution dated 2nd July,2026 duly signed by Mr. Ashish Narayan Sakalkar, Managing Director, holding DIN: 06601011.

b) Value Definition:

Business Valuation can be undertaken in a variety of contexts and for variety of purposes. To begin with any valuation purpose, it is most pertinent to identify the type of value relevant to the transaction/ case as different standards of value would yield different valuation figure for same business interest.

c) Basis of Valuation:

According to IVS 104.10.1 Bases of Value (sometimes called standards of value) describe the fundamental premises on which the reported values will be based. It is critical that the basis (or bases) of value be appropriate to the terms and purpose of the valuation assignment, as the basis of value may influence or dictate valuer's selection of methods, inputs and assumptions, and the ultimate opinion of value.

IVS 104.20.1 (a) provides us with the following IVS defined bases of value:

Market Value (section 30),
Market Rent (Section 40),
Equitable Value (section 50),
Investment Value/ Worth (section 60),
Synergistic Value (section 70) and
Liquidation Value (section 80)

IVS 104.20.1 (b) (1) Fair Value (International Financial Reporting Standards) (section 90).

According to IVS 104.20.2 *Valuers* must choose the relevant basis (or bases) of *value* according to the terms and *purpose of the valuation* assignment. The *valuer's* choice of a basis (or bases) of value *should* consider instructions and input received from the *client* and/or its representatives.

In this case, the client has specifically assigned the job to the valuer to estimate the fair value of the equity shares for determining floor price for the purpose of preferential allotment of Equity Shares.

Therefore, the relevant basis of value of this assignment should be "Fair Market Value" which is identical to the Market Value basis as defined in the International Valuation Standards. The present valuation of the Company is undertaken on a Going Concern premise.

3. Background of the Information:

a) Company Overview:

Asston Pharmaceuticals Limited ("the Company") is a public limited company incorporated on 16 April 2019 and having its registered office at Office No. A-431, Balaji Bhavan, 4th Floor, Plot No. 42A, Sector-11, CBD Belapur, Navi Mumbai, Maharashtra- 400614. The equity shares of the Company are listed on the BSE SME Platform under Scrip Code **544445** and ISIN **NE0SJX01015**.

The Company is engaged in the manufacturing, marketing, contract manufacturing and export of pharmaceutical and nutraceutical products. Its product portfolio includes tablets, capsules, oral liquids, ointments, creams, gels, lotions, dry syrups, sachets, injectables (LVP and SVP), eye drops, paediatric formulations, generic medicines and nutraceutical products. In addition to manufacturing products under its own brands, the Company undertakes loan licence and contract manufacturing for various pharmaceutical marketers on a principal-to-principal basis.

The Company presently operates two manufacturing facilities located at Ambernath, Maharashtra. It holds over 150 registered trademarks relating to its pharmaceutical formulations and maintains certifications and accreditations from the relevant regulatory authorities, including State and Central FDA approvals, Quality Management System (QMS) compliance and NQA certification. Its manufacturing operations comply with applicable environmental norms and fall within the prescribed Orange and Green categories.

The Company commenced operations in 2019 primarily to manufacture pharmaceutical products for export markets. On 1 April 2024, it acquired the plant and machinery of Ferron Lifecare Private Limited to strengthen its nutraceutical manufacturing capabilities. Subsequently, the Company was converted into a public limited company on 29 August 2024 under the name Asston Pharmaceuticals Limited and received FDA approval for its Ambernath pharmaceutical manufacturing facility on 2 December 2024.

Capital Structure of the Company (As per MCA database)

Particulars	No. of Shares	Amount (in Rs.)
Authorized Capital		
Equity Shares of Rs. 10/- each	1,10,00,000	11,00,00,000
Issued, Subscribed and Paid-up capital		
Equity Shares of Rs. 10/- each	85,12,360	8,51,23,600

Shareholding Pattern as per latest shareholding pattern filed with BSE:

Sr. No.	Details of Shareholding	No. of shares held	Percentage Shareholding
1	Promoter and Promoter Group	43,12,480	50.66
2	Public	41,99,880	49.34
	Total	**85,12,360**	**100.00**

Directors and Key Managerial Personnel of the Company:

Sr. No.	DIN/PAN	Name	Designation	Date of Appointment
1	06601011	Ashish Narayan Sakalkar	Managing Director	16/04/2019
2	02691527	Saili Jayaram More	Whole-time director and CEO	16/04/2019
3	11344916	Yogesh Prakash Supekar	Non- Executive Director	16/10/2025
4	10611758	Rishabh Kumar Jain	Independent Director	20/09/2024
5	10767960	Vijaya E Shahapurkar	Independent Director	20/09/2024
6	08685214	Sachin Chandrakant Badakh	Non-Executive Director	17/05/2024
7	08759617	Yashvardhan Nitin Tupe	Non- Executive Director	30/03/2026
8	11627247	Sandip Sharma	Independent Director	30/03/2026

4. Identity of the Valuer

1.	Name of the Valuer	:	Ms. Amninder Kaur
2.	Address	:	69, Phase 3, SKS Nagar, Ludhiana-141013.
3.	Contact Details	:	Mobile: 89688-83634 Email: cs.kauramninder@gmail.com
4.	Credentials	:	ICSI Registered Valuer (ICSI RVO/COP/SFA0620/197)
5.	Qualifications	:	B. Com, PGDIM, CS, IBBI Qualified Registered Valuer.

5. Disclosure of Interest or Conflict, if any

The Valuer or any of her relative or associate is not related or associated with the subject company. The Valuer has conducted the valuation independent of external influences.

6. Date of Appointment, Valuation Date and Date of Report

Date of Appointment	:	July 02, 2026.
Valuation Date	:	July 01, 2026.

Registered Valuer SFA ★ Amninder Kaur ★ Regd. No. IBBI/RV/03/2021/14025

Date of Report : July 02, 2026.

7. Nature and Sources of Data/ Information used or relied upon

Nature of underlying data	:	Primary Data
Source of data	:	As provided by Company's Management and data available on BSE and MCA
Quality of Underlying Data	:	Dependable

Documents/ Information used or relied upon:

a) Published Audited Financial Statements of Asston Pharmaceuticals Limited for the FY 2026, 2025 and 2024.
b) Latest shareholding pattern of the Company available on BSE.
c) Annual Report of the Company.
d) Trading data from BSE for computing Volume Weighted Average Prices of 90 days and 10 days preceding the relevant date.
e) SEBI Pricing guidelines as per ICDR Regulations, 2018.
f) Other business-related information and explanations given during the process of valuation as was required for filling gaps.
g) Reliance has been placed on the verbal explanations and information given to us by the management.
h) Management Representation Letter.

8. Procedure adopted in carrying out the valuation and Valuation Approach and Methodology

a) Procedure adopted

i. Receipt of intimation of about appointment and acceptance of proposal.
ii. Execution of valuation engagement letter and providing checklist of the required documents.
iii. Receipt of the documents as per the checklist leading to primary study including business analysis.
iv. Collection of additional documents.
v. Determining valuation methods and approach.
vi. Report preparation and its validation.

b) Valuation Standard Followed: International Valuation Standards issued by International Valuation Standards Council (IVSC) and guidance note on valuation issued by the ICSI Registered Valuers Organization have been followed.

c) Valuation approaches and Methodology used:

Valuation of a business is not an exact science and ultimately depends upon what is worth to a serious investor or buyer who may be prepared to pay a

Registered Valuer SFA Amninder Kaur Regd. No IBBI/RV/03/2021/14025 substantial goodwill. This exercise may be carried out using various methodologies, the relative emphasis of each varying with:

- Whether the entity is listed on a stock exchange
- Industry to which the company belongs
- Past track record of the business and the ease with which the growth rate in cash flows to perpetuity can be estimated
- Extent to which industry and comparable company information is available

The result of this exercise could vary significantly depending upon the basis used, the specific circumstances and professional judgment of the valuer. In respect of going concerns, certain valuation techniques have evolved over time and are commonly in vogue. These approaches can be broadly categorized as follows:
1. Cost Approach
2. Income Approach
3. Market Approach

Cost Approach

The Cost Approach provides an indication of *value* using the economic principle that a buyer will pay no more for an *asset* than the cost to obtain an *asset* of equal utility, whether by purchase or by construction, unless undue time, inconvenience, risk or other factors are involved. The approach provides an indication of *value* by calculating the current replacement or reproduction cost of an *asset* and making deductions for physical deterioration and all other relevant forms of obsolescencies. This valuation technique is based on the value of underlying net assets of the business, either on a book value basis or realizable value basis or replacement cost basis. Examples of situations where a valuer applies the cost approach are:

- an asset can be quickly recreated with substantially the same utility as the asset to be valued;
- in case where liquidation value is to be determined; or
- income approach and/or market approach cannot be used

The following are the most commonly used valuation methods under the Cost approach:

- Replacement Cost Method
- Reproduction Cost Method
- Net Asset Method

In the present case, future earnings are not completely based on underlying assets. Therefore, we given 10% weightage to this method of valuation.

Valuation under NAV Approach (Based on Consolidated Financials as on 31st March, 2026)

Particulars	**Amount (in Rs. Lakhs)**
Equity Share Capital	851.24
Other Equity	3034.99
Net Asset Value	386.23
No. of Equity Shares of Rs. 10 each	8512360
Net Value of Equity Share in Rs.	45.65
Net Value of Equity Share in Rs. (Rounded Off)	**45.70**

Income Approach

The income approach is widely used for valuation under "Going Concern" basis. It focuses on the income generated by the Company in the past as well as its future earning capability. The discount or capitalization rate converts the stream of benefits into present value. There are several different income approaches, including Capitalization of Earnings or Cash Flows, Discounted Future Cash Flows ("DCF"). Under the DCF Method, the business is valued by discounting its free cash flows for the explicit forecast period and the perpetuity value thereafter. The free cash flows in the explicit period and those in perpetuity are discounted by the Weighted Average Cost of Capital (WACC). The WACC based on an optimal viz a viz actual capital structure, is an appropriate rate of discount to calculate the present value of the future cash flows. The perpetuity value is calculated based on the business potential for future growth beyond the explicit forecast period.

DCF method will require sharing of projections by the Company which is likely to include unpublished price sensitive information. Therefore, this method is not used for valuation.

The valuation has been carried out using the Profit Earning Capacity Value (PECV) Method under the Income Approach. Under this method, the maintainable profit-earning capacity of the Company has been capitalized by applying the forward Price-to-Earnings (P/E) multiple of the pharmaceutical industry derived from the industry database published by Professor Aswath Damodaran. The selected multiple has been considered appropriate having regard to the nature of the Company's business, industry characteristics and future earning potential, to arrive at the equity value of the Company.

*A weight of 40% has been assigned to the **Profit Earning Capacity Value (PECV) Method** under the Income Approach, as the Company is an operating and profit-generating enterprise with an established business model, manufacturing infrastructure and continuing operations.*

Based on Standalone Audited Financials as on 31st March 2025-26, 2024-25 and 2023-24.

Amount (in Rs. Lakhs)

Particulars	**2024-25**	**2023-24**	**2022-23**	**Total**
Revenue from Operations	2547.00	2503.92	1602.80	
Profit before Tax	459.00	501.60	325.01	
Weights	3	2	1	6
Product	1377	1003.2	325.01	2705.21
Weighted Average Profit before tax				450.86
Taxes @ 25.17%				113.48
Future Maintainable Profit				337.38
PE Multiple (Based on Damodaran Industry Averages)				31.63
Equity Value				10671.48
No. of Equity Shares				8512360
Fair Value as per PECV Method (Rounded Off) In INR				**125.36**

PE Ratio Source: peIndia.xls

Market Approach

Market Price Method

The market price of an equity share quoted on a stock exchange is normally considered as the value of Equity Share of the company, if such shares are frequently traded. Equity shares of Asston Pharmaceuticals Limited are listed and traded on BSE since 14th July, 2025 and are frequently traded since then.

*A weight of **50%** has been assigned to the **Market Price Method**, as the equity shares of the Company are listed on the BSE SME Platform and are traded on a recognized stock exchange.*

Weighted Average Price of the date preceding the relevant date (1st July, 2026) as on 30th June, 2026 is Rs. 80.25 and is taken as Fair Value of Equity share.

Extract of pricing provisions of SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2018:

Regulation 166 A. (1) Any preferential issue, which may result in a change in control or allotment of more than five percent of the post issue fully diluted share capital of the issuer, to an allottee or to allottees acting in concert, shall require a valuation report from an independent registered valuer and consider the same for determining the price

Regulation 164. (1) If the equity shares of the issuer have been listed on a recognised stock exchange for a period of 90 trading days or more as on the

Registered Valuer SFA ★ Amninder Kaur ★ Regd. No. IBBI/RV/03/2021/14025

relevant date, the price of the equity shares to be allotted pursuant to the preferential issue shall be not less than higher of the following:

a) the 90 trading days' volume weighted average price of the related equity shares quoted on the recognised stock exchange preceding the relevant date; or
b) the 10 trading days' volume weighted average prices of the related equity shares quoted on a recognised stock exchange preceding the relevant date.

Opinion on the Valuation:

Fair Value as per Reg 166A of ICDR Regulations			
Method of Valuation	**Value of per Equity Share (in Rs.)**	**Weightage**	**Weighted Value (in Rs.)**
Asset Approach (A)	45.65	10%	4.57
PECV (B)	125.36	40%	50.15
Weighted Average Price (C)	80.25	50%	40.13
Fair Value of Equity Share (A+B+C)			94.84
Fair Value as per Reg. 166A (D) (Rounded Off)			**Rs. 95**

Valuation under Regulation 164 of ICDR Regulations has been arrived at by considering data between 14th January, 2026 to 30th June, 2026, (90 trading days) as follows:

Fair Value as per Reg 164 of ICDR Regulations	**Source : BSE Data**
90 trading days' Value	Rs. 73,258,360
90 trading days' Volume	969,000
10 trading days' Value	Rs. 24,635,150
10 trading days' Volume	353,000
90 trading days' Volume Weighted Average Price (E)	Rs. 75.60
10 trading days' Volume Weighted Average Price (F)	Rs. 69.79
Value as per Reg. 164 (Higher of (E) or (F) above)	Rs. 75.60
Fair Value as per Reg 164 (G) (Rounded Off)	**Rs. 76**

The Shares of the Company got listed on 16th July, 2025 and since then are frequently traded and the trading data has been annexed to this report as **Annexure I.**

	Per Share Value (In Rs.)
Fair Value of Equity Shares as per Regulation 166A of ICDR Regulations - (D)	95
Fair Value of Equity Shares as per Regulation 164 of ICDR Regulations - (G)	76
Minimum Price at which shares can be issued (Higher of D or G above)	**Rs. 95**

As per the valuation methodologies Fair Value of equity share of the Company is determined at Rs. 95.00 per share. The floor price as per minimum pricing guidelines specified in regulation 164 and regulation 166A of ICDR Regulations is Rs. 95.00 per share.

9. Restrictions on the use of the Report

This report is subject to the scope, assumptions, exclusions, caveats, limitations and disclaimers detailed hereinafter in Point No. 10. As such, the report is to be read in totality, and not in parts, in conjunction with the relevant documents referred to herein and specifically used for the purpose mentioned in the report.

10. Caveats, Limitations and Disclaimers

a. Purpose and Scope

This valuation report has been prepared solely for the specific purpose outlined in the report and is valid only as of the valuation date. It does not constitute an offer or recommendation to buy or sell any securities, nor does it confirm or opine on any proposed transaction structure.

This report is intended to be read in its entirety and in conjunction with supporting documents, and should not be used or relied upon in isolation.

The analysis and opinions herein are based on information provided by the management of the Company, as well as publicly available and other relevant sources. No independent verification or audit of such information has been conducted by us.

b. Reliance on Information and Representations

We have relied upon financial, operational, and other data provided by the management. The accuracy, reliability, and completeness of such information are the responsibility of the Company. Our conclusions are contingent upon the assumptions that the data provided is materially correct.

No due diligence or forensic review was undertaken as part of this assignment. We have not investigated the title of the assets, existence of encumbrances, or any legal claims or litigations. We have received confirmation that there are no events, demands, or legal or other decisions pending against the Company that

Registered Valuer SFA Amninder Kaur Regd. No IBBI/RV/03/2021/14025 could materially impact the financial position as of the valuation date or the future profitability of the Company.

Forecasts and projections provided by management have been assumed to be reasonable, but we do not provide assurance on their achievability. The valuation is sensitive to the assumptions made by the management and any material deviation may impact the outcome.

c. Methodology and Judgement

Valuation is not an exact science and involves significant professional judgment. Various external factors, including market sentiment, competition, management effectiveness, and broader economic conditions, may materially influence valuation conclusions.

Different valuers may adopt different assumptions leading to different value outcomes. The conclusions of this report represent a professional opinion based on prevailing conditions and available data.

d. Limitations of Use

This report is confidential and intended only for the use of the appointing authority and regulatory bodies as required. It must not be shared, quoted, or disclosed without prior written consent, except where required under applicable laws.

No part of this report should be interpreted as legal, accounting, or tax advice. Separate expert advice must be sought for such matters. The valuation does not assess the commercial rationale or comparative merits of any proposed transaction.

e. Liability and Legal Considerations

We accept no liability to any third party for unauthorized use of this report. The responsibility for the final transaction decision lies solely with the Board of Directors or approving authority.

We shall not be liable for any loss arising from fraudulent acts, misrepresentations, or omissions on the part of the Company, its directors, or any other stakeholders.

Class action suits, as contemplated under international legal frameworks, are not applicable to Registered Valuers operating under the regulatory framework of the Companies Act, 2013 and the rules prescribed thereunder in India. Accordingly, no liability whether collective or otherwise shall arise against the undersigned Valuer in the nature of a class action. Any claims, if any, shall be governed strictly by Indian law and shall be subject to the terms of the engagement and applicable legal remedies under Indian jurisdiction only.

Registered Valuer SFA Amninder Kaur Regd No IBBI RV 03/2021/14025

This report is subject to Indian law and may be disclosed to regulatory authorities if required. The fees for this engagement are not contingent on the valuation outcome.

Annexure I

Trading Days	Date	Open Price	High Price	Low Price	WAP	No.of Shares	Total Turnover (Rs.)
1	30-Jun-26	81.00	81.00	80.00	80.25	6000	481510
2	29-Jun-26	82.00	85.00	82.00	84.36	7000	590490
3	25-Jun-26	81.00	81.00	81.00	81.00	1000	81000
4	23-Jun-26	82.00	82.00	82.00	82.00	3000	246000
5	17-Jun-26	80.00	82.00	80.00	81.33	3000	244000
6	16-Jun-26	70.01	79.00	70.01	77.25	7000	540760
7	15-Jun-26	82.05	83.00	82.05	82.53	2000	165050
8	12-Jun-26	75.00	83.01	61.02	68.72	296000	20339710
9	11-Jun-26	73.00	74.00	73.00	73.67	3000	221000
10	08-Jun-26	68.00	72.97	67.01	69.03	25000	1725630
11	05-Jun-26	73.00	73.00	68.01	69.20	8000	553610
12	04-Jun-26	73.01	73.01	73.01	73.01	2000	146020
13	27-May-26	75.00	75.00	73.01	74.01	2000	148010
14	26-May-26	70.00	70.00	70.00	70.00	1000	70000
15	22-May-26	72.80	72.80	72.80	72.80	1000	72800
16	20-May-26	72.67	72.67	72.67	72.67	1000	72670
17	19-May-26	72.65	72.70	72.65	72.66	4000	290650
18	18-May-26	73.00	73.00	73.00	73.00	4000	292000
19	14-May-26	76.75	76.75	76.75	76.75	2000	153500
20	13-May-26	76.50	76.50	76.00	76.17	3000	228500
21	12-May-26	79.00	79.00	79.00	79.00	2000	158000
22	08-May-26	79.94	79.94	79.94	79.94	1000	79940
23	07-May-26	79.94	79.94	79.94	79.94	1000	79940
24	06-May-26	80.00	80.00	80.00	80.00	3000	240000
25	05-May-26	80.00	80.00	80.00	80.00	2000	160000
26	04-May-26	82.50	83.00	79.00	81.75	6000	490510
27	30-Apr-26	77.50	80.90	77.50	79.20	2000	158400
28	29-Apr-26	81.00	81.00	81.00	81.00	1000	81000
29	28-Apr-26	77.77	77.77	77.77	77.77	1000	77770
30	27-Apr-26	87.00	87.00	77.00	79.49	18000	1430820
31	24-Apr-26	81.00	84.00	81.00	81.44	9000	733000
32	22-Apr-26	78.00	78.00	78.00	78.00	1000	78000
33	20-Apr-26	79.30	79.30	79.30	79.30	2000	158600
34	17-Apr-26	79.00	81.50	77.15	79.95	14000	1119290
35	16-Apr-26	84.00	84.00	73.01	75.83	40000	3033040
36	15-Apr-26	88.00	88.00	83.35	85.67	5000	428350
37	13-Apr-26	86.90	95.65	85.00	88.90	9000	800130
38	09-Apr-26	87.29	87.29	87.29	87.29	1000	87290

Registered Valuer SFA ★ Amninder Kaur ★ Regd. No. IBBI/RV/03/2021/14025

39	06-Apr-26	75.15	76.01	75.00	75.29	4000	301160
40	02-Apr-26	78.00	78.00	78.00	78.00	1000	78000
41	01-Apr-26	79.98	80.01	75.00	79.31	9000	713780
42	30-Mar-26	69.00	73.00	65.20	67.50	14000	945060
43	27-Mar-26	69.00	71.00	68.50	69.57	23000	1600120
44	25-Mar-26	73.90	75.00	70.00	71.80	10000	718000
45	24-Mar-26	75.50	75.50	70.00	72.76	13000	945840
46	23-Mar-26	69.00	72.00	68.00	69.36	11000	762930
47	20-Mar-26	77.50	77.50	70.10	72.92	9000	656250
48	19-Mar-26	73.00	73.00	72.50	72.57	9000	653100
49	18-Mar-26	75.26	77.00	70.00	73.58	11000	809380
50	17-Mar-26	74.00	74.00	74.00	74.00	2000	148000
51	16-Mar-26	75.00	77.00	75.00	75.50	4000	302000
52	13-Mar-26	70.26	76.00	70.26	74.69	8000	597520
53	12-Mar-26	78.00	78.05	78.00	78.03	16000	1248500
54	11-Mar-26	79.00	81.00	78.01	79.65	10000	796530
55	10-Mar-26	79.00	82.00	79.00	80.33	3000	241000
56	09-Mar-26	78.00	78.00	78.00	78.00	4000	312000
57	06-Mar-26	81.00	81.00	80.50	80.88	4000	323500
58	05-Mar-26	78.00	80.50	78.00	79.25	2000	158500
59	04-Mar-26	79.00	80.00	75.24	78.15	12000	937850
60	02-Mar-26	80.00	80.00	77.00	79.20	5000	396000
61	27-Feb-26	85.00	85.00	85.00	85.00	1000	85000
62	26-Feb-26	82.00	82.00	76.01	79.88	6000	479260
63	25-Feb-26	80.00	82.00	80.00	81.48	25000	2037000
64	24-Feb-26	82.00	82.00	82.00	82.00	1000	82000
65	20-Feb-26	80.10	83.00	80.10	82.39	8000	659100
66	19-Feb-26	82.80	83.00	80.00	82.44	19000	1566400
67	18-Feb-26	76.50	82.00	76.50	78.92	6000	473510
68	17-Feb-26	82.00	82.00	80.60	81.05	6000	486300
69	16-Feb-26	80.01	82.00	80.01	80.96	7000	566710
70	12-Feb-26	87.00	87.00	81.80	84.28	5000	421400
71	11-Feb-26	86.00	86.00	80.50	82.22	13000	1068800
72	10-Feb-26	79.05	81.00	79.05	79.70	3000	239100
73	09-Feb-26	78.63	78.63	78.63	78.63	1000	78630
74	06-Feb-26	80.00	83.00	80.00	80.87	5000	404340
75	05-Feb-26	80.00	80.00	79.99	80.00	4000	319990
76	04-Feb-26	79.01	80.00	79.01	79.90	11000	878920
77	03-Feb-26	98.00	98.00	79.06	82.39	18000	1482950
78	02-Feb-26	95.80	95.80	79.99	81.01	25000	2025250
79	01-Feb-26	82.99	83.00	81.50	82.72	9000	744470
80	30-Jan-26	88.60	88.60	79.80	81.67	31000	2531890

Registered Valuer SFA
Amninder Kaur
Regd. No. IBBI/RV/03/2021/14025

81	29-Jan-26	85.00	85.00	80.20	83.92	25000	2098000
82	28-Jan-26	85.65	86.15	85.65	86.05	5000	430250
83	27-Jan-26	85.35	86.00	85.30	85.55	3000	256650
84	23-Jan-26	85.23	85.30	85.23	85.27	3000	255810
85	22-Jan-26	88.00	88.00	85.00	85.63	8000	685040
86	21-Jan-26	84.15	85.00	84.15	84.74	13000	1101600
87	20-Jan-26	83.80	84.15	83.80	84.08	10000	840800
88	19-Jan-26	84.49	84.49	83.80	84.06	3000	252180
89	16-Jan-26	82.50	84.49	82.50	83.50	2000	166990
90	14-Jan-26	83.50	84.01	83.50	83.80	10000	838010
		90 Days' Total				**969,000**	**73,258,360**
		90 Days ' VWAP			**75.60**		
		10 Days' Total				**353,000**	**24,635,150**
		10 Days' VWAP			**69.79**		
		Higher of (A) or (B) above			**75.60**		

Frequency of Trading

Trading Days	Date	Open Price	High Price	Low Price	Close Price	WAP	No. of Shares	Total Turnover (Rs.)
1	30-Jun-26	81.00	81.00	80.00	80.00	80.25	6000	481510
2	29-Jun-26	82.00	85.00	82.00	83.50	84.36	7000	590490
3	25-Jun-26	81.00	81.00	81.00	81.00	81.00	1000	81000
4	23-Jun-26	82.00	82.00	82.00	82.00	82.00	3000	246000
5	17-Jun-26	80.00	82.00	80.00	82.00	81.33	3000	244000
6	16-Jun-26	70.01	79.00	70.01	78.00	77.25	7000	540760
7	15-Jun-26	82.05	83.00	82.05	82.53	82.53	2000	165050
8	12-Jun-26	75.00	83.01	61.02	82.78	68.72	296000	20339710
9	11-Jun-26	73.00	74.00	73.00	73.67	73.67	3000	221000
10	08-Jun-26	68.00	72.97	67.01	71.70	69.03	25000	1725630
11	05-Jun-26	73.00	73.00	68.01	68.66	69.20	8000	553610
12	04-Jun-26	73.01	73.01	73.01	73.01	73.01	2000	146020
13	27-May-26	75.00	75.00	73.01	73.01	74.01	2000	148010
14	26-May-26	70.00	70.00	70.00	70.00	70.00	1000	70000
15	22-May-26	72.80	72.80	72.80	72.80	72.80	1000	72800
16	20-May-26	72.67	72.67	72.67	72.67	72.67	1000	72670

Registered Valuer SFA
Amninder Kaur

17	19-May-26	72.65	72.70	72.65	72.67	72.66	4000	290650
18	18-May-26	73.00	73.00	73.00	73.00	73.00	4000	292000
19	14-May-26	76.75	76.75	76.75	76.75	76.75	2000	153500
20	13-May-26	76.50	76.50	76.00	76.17	76.17	3000	228500
21	12-May-26	79.00	79.00	79.00	79.00	79.00	2000	158000
22	08-May-26	79.94	79.94	79.94	79.94	79.94	1000	79940
23	07-May-26	79.94	79.94	79.94	79.94	79.94	1000	79940
24	06-May-26	80.00	80.00	80.00	80.00	80.00	3000	240000
25	05-May-26	80.00	80.00	80.00	80.00	80.00	2000	160000
26	04-May-26	82.50	83.00	79.00	79.00	81.75	6000	490510
27	30-Apr-26	77.50	80.90	77.50	80.90	79.20	2000	158400
28	29-Apr-26	81.00	81.00	81.00	81.00	81.00	1000	81000
29	28-Apr-26	77.77	77.77	77.77	77.77	77.77	1000	77770
30	27-Apr-26	87.00	87.00	77.00	77.22	79.49	18000	1430820
31	24-Apr-26	81.00	84.00	81.00	81.00	81.44	9000	733000
32	22-Apr-26	78.00	78.00	78.00	78.00	78.00	1000	78000
33	20-Apr-26	79.30	79.30	79.30	79.30	79.30	2000	158600
34	17-Apr-26	79.00	81.50	77.15	79.30	79.95	14000	1119290
35	16-Apr-26	84.00	84.00	73.01	75.40	75.83	40000	3033040
36	15-Apr-26	88.00	88.00	83.35	84.00	85.67	5000	428350
37	13-Apr-26	86.90	95.65	85.00	88.00	88.90	9000	800130
38	09-Apr-26	87.29	87.29	87.29	87.29	87.29	1000	87290
39	06-Apr-26	75.15	76.01	75.00	76.01	75.29	4000	301160
40	02-Apr-26	78.00	78.00	78.00	78.00	78.00	1000	78000
41	01-Apr-26	79.98	80.01	75.00	78.80	79.31	9000	713780
42	30-Mar-26	69.00	73.00	65.20	73.00	67.50	14000	945060
43	27-Mar-26	69.00	71.00	68.50	70.38	69.57	23000	1600120
44	25-Mar-26	73.90	75.00	70.00	70.00	71.80	10000	718000
45	24-Mar-26	75.50	75.50	70.00	70.00	72.76	13000	945840
46	23-Mar-26	69.00	72.00	68.00	68.18	69.36	11000	762930
47	20-Mar-26	77.50	77.50	70.10	70.15	72.92	9000	656250
48	19-Mar-26	73.00	73.00	72.50	72.50	72.57	9000	653100
49	18-Mar-26	75.26	77.00	70.00	74.43	73.58	11000	809380
50	17-Mar-26	74.00	74.00	74.00	74.00	74.00	2000	148000
51	16-Mar-26	75.00	77.00	75.00	77.00	75.50	4000	302000
52	13-Mar-26	70.26	76.00	70.26	75.00	74.69	8000	597520
53	12-Mar-26	78.00	78.05	78.00	78.00	78.03	16000	1248500
54	11-Mar-26	79.00	81.00	78.01	78.50	79.65	10000	796530
55	10-Mar-26	79.00	82.00	79.00	82.00	80.33	3000	241000
56	09-Mar-26	78.00	78.00	78.00	78.00	78.00	4000	312000
57	06-Mar-26	81.00	81.00	80.50	80.50	80.88	4000	323500
58	05-Mar-26	78.00	80.50	78.00	79.25	79.25	2000	158500

Registered Valuer SFA
Amninder Kaur
Regd. No IBBI/RV/03/2021/14025

59	04-Mar-26	79.00	80.00	75.24	75.63	78.15	12000	937850
60	02-Mar-26	80.00	80.00	77.00	80.00	79.20	5000	396000
61	27-Feb-26	85.00	85.00	85.00	85.00	85.00	1000	85000
62	26-Feb-26	82.00	82.00	76.01	80.00	79.88	6000	479260
63	25-Feb-26	80.00	82.00	80.00	82.00	81.48	25000	2037000
64	24-Feb-26	82.00	82.00	82.00	82.00	82.00	1000	82000
65	20-Feb-26	80.10	83.00	80.10	82.00	82.39	8000	659100
66	19-Feb-26	82.80	83.00	80.00	82.71	82.44	19000	1566400
67	18-Feb-26	76.50	82.00	76.50	82.00	78.92	6000	473510
68	17-Feb-26	82.00	82.00	80.60	80.90	81.05	6000	486300
69	16-Feb-26	80.01	82.00	80.01	82.00	80.96	7000	566710
70	12-Feb-26	87.00	87.00	81.80	81.95	84.28	5000	421400
71	11-Feb-26	86.00	86.00	80.50	81.80	82.22	13000	1068800
72	10-Feb-26	79.05	81.00	79.05	81.00	79.70	3000	239100
73	09-Feb-26	78.63	78.63	78.63	78.63	78.63	1000	78630
74	06-Feb-26	80.00	83.00	80.00	81.34	80.87	5000	404340
75	05-Feb-26	80.00	80.00	79.99	80.00	80.00	4000	319990
76	04-Feb-26	79.01	80.00	79.01	80.00	79.90	11000	878920
77	03-Feb-26	98.00	98.00	79.06	80.00	82.39	18000	1482950
78	02-Feb-26	95.80	95.80	79.99	84.00	81.01	25000	2025250
79	01-Feb-26	82.99	83.00	81.50	83.00	82.72	9000	744470
80	30-Jan-26	88.60	88.60	79.80	82.99	81.67	31000	2531890
81	29-Jan-26	85.00	85.00	80.20	81.37	83.92	25000	2098000
82	28-Jan-26	85.65	86.15	85.65	86.15	86.05	5000	430250
83	27-Jan-26	85.35	86.00	85.30	85.55	85.55	3000	256650
84	23-Jan-26	85.23	85.30	85.23	85.30	85.27	3000	255810
85	22-Jan-26	88.00	88.00	85.00	85.20	85.63	8000	685040
86	21-Jan-26	84.15	85.00	84.15	85.00	84.74	13000	1101600
87	20-Jan-26	83.80	84.15	83.80	84.15	84.08	10000	840800
88	19-Jan-26	84.49	84.49	83.80	83.80	84.06	3000	252180
89	16-Jan-26	82.50	84.49	82.50	84.49	83.50	2000	166990
90	14-Jan-26	83.50	84.01	83.50	83.80	83.80	10000	838010
91	13-Jan-26	84.01	84.01	84.00	84.00	84.01	2000	168010
92	12-Jan-26	78.10	91.51	78.10	84.00	84.02	13000	1092310
93	08-Jan-26	88.00	88.00	82.60	84.61	84.45	4000	337810
94	07-Jan-26	88.00	88.00	88.00	88.00	88.00	1000	88000
95	06-Jan-26	85.00	87.50	81.99	87.50	86.07	6000	516420
96	05-Jan-26	84.00	84.00	84.00	84.00	84.00	1000	84000
97	02-Jan-26	82.57	89.50	80.00	87.10	84.17	18000	1515040
98	01-Jan-26	82.60	84.80	81.81	82.57	83.90	64000	5369690
99	31-Dec-25	84.50	84.50	82.53	82.53	83.95	19000	1595060
100	30-Dec-25	84.50	84.50	84.50	84.50	84.50	8000	676000

101	26-Dec-25	86.00	86.00	84.00	84.00	84.43	14000	1182000
102	24-Dec-25	86.10	86.10	84.00	84.21	85.18	26000	2214650
103	23-Dec-25	90.00	99.99	86.00	86.06	89.34	13000	1161400
104	18-Dec-25	82.43	89.00	82.43	88.81	87.17	29000	2528070
105	16-Dec-25	86.01	86.50	83.31	85.00	85.40	7000	597770
106	15-Dec-25	86.88	86.88	85.00	85.00	85.96	3000	257880
107	12-Dec-25	87.80	87.80	87.80	87.80	87.80	1000	87800
108	11-Dec-25	86.70	88.99	86.69	88.99	87.46	3000	262380
109	10-Dec-25	88.20	88.21	85.01	86.69	87.45	8000	699570
110	09-Dec-25	90.21	90.21	86.11	89.99	89.56	7000	626930
111	08-Dec-25	90.27	94.25	85.01	90.21	89.69	16000	1435080
112	05-Dec-25	94.85	95.00	90.25	90.28	92.30	9000	830720
113	04-Dec-25	93.24	98.52	93.24	95.13	95.86	12000	1150300
114	03-Dec-25	105.00	105.00	92.99	98.99	99.43	25000	2485850
115	02-Dec-25	100.00	105.00	97.04	104.62	102.39	83000	8498130
116	01-Dec-25	92.10	97.47	92.10	97.00	96.11	5000	480570
117	28-Nov-25	93.46	93.46	92.10	92.10	92.78	2000	185560
118	27-Nov-25	99.95	99.95	92.69	93.46	94.99	20000	1899820
119	26-Nov-25	87.94	100.00	87.94	99.96	96.97	82000	7951400
120	25-Nov-25	85.82	88.00	84.20	86.10	86.74	21000	1821590
121	24-Nov-25	84.00	84.00	84.00	84.00	84.00	2000	168000
122	21-Nov-25	85.50	85.80	84.00	84.00	85.18	6000	511100
123	20-Nov-25	83.30	86.00	83.30	86.00	85.58	13000	1112500
124	19-Nov-25	89.50	89.50	84.00	85.00	85.69	33000	2827680
125	18-Nov-25	85.00	87.80	84.01	87.00	86.36	40000	3454370
126	17-Nov-25	77.85	84.45	77.85	81.68	81.39	11000	895300
127	14-Nov-25	76.05	77.78	76.05	77.77	76.73	7000	537080
128	13-Nov-25	79.45	79.45	77.26	77.60	78.40	4000	313610
129	12-Nov-25	77.00	80.40	77.00	79.95	79.60	6000	477620
130	11-Nov-25	77.00	77.10	75.21	75.60	76.20	7000	533410
131	10-Nov-25	78.00	79.00	77.00	77.10	77.60	32000	2483260
132	07-Nov-25	80.00	82.00	77.05	77.69	78.40	34000	2665710
133	06-Nov-25	80.00	82.50	80.00	80.00	80.56	16000	1288980
134	04-Nov-25	82.65	82.65	82.65	82.65	82.65	1000	82650
135	31-Oct-25	83.10	83.10	83.10	83.10	83.10	2000	166200
136	30-Oct-25	81.21	83.10	81.21	83.05	82.06	8000	656500
137	29-Oct-25	82.55	83.50	80.60	81.11	82.46	31000	2556180
138	28-Oct-25	85.10	87.80	83.50	84.01	84.35	40000	3374160
139	27-Oct-25	85.11	87.90	83.65	87.90	85.52	15000	1282730
140	24-Oct-25	85.30	89.99	85.30	88.90	87.21	10000	872120
141	23-Oct-25	86.85	87.95	86.00	86.00	86.53	8000	692200
142	21-Oct-25	90.00	90.00	87.30	87.30	89.08	8000	712600

Registered Valuer SFA
Amninder Kaur
Regd. No. IBBI RV 2021/14025

143	20-Oct-25	93.99	95.00	87.00	89.20	90.16	40000	3606230
144	17-Oct-25	88.03	89.99	80.10	87.90	83.87	55000	4612960
145	16-Oct-25	94.00	94.00	88.00	88.02	90.03	19000	1710530
146	15-Oct-25	91.20	92.50	91.20	91.90	91.55	8000	732430
147	14-Oct-25	95.01	95.01	93.00	93.45	93.99	7000	657960
148	13-Oct-25	95.80	95.80	95.00	95.00	95.40	2000	190800
149	10-Oct-25	96.50	99.99	96.50	98.00	98.42	8000	787390
150	09-Oct-25	91.10	96.50	91.10	95.74	94.96	7000	664740
151	08-Oct-25	97.00	98.00	95.10	97.92	96.54	6000	579220
152	07-Oct-25	98.00	98.00	96.05	97.00	96.98	10000	969780
153	06-Oct-25	101.90	101.90	99.60	99.60	100.14	6000	600850
154	01-Oct-25	99.00	102.50	99.00	102.00	101.00	6000	606000
155	30-Sep-25	106.45	106.45	98.00	98.30	100.36	10000	1003560
156	29-Sep-25	96.20	96.50	96.20	96.50	96.35	4000	385400
157	26-Sep-25	96.01	96.15	96.01	96.13	96.06	5000	480280
158	25-Sep-25	97.15	99.80	97.15	99.80	98.19	6000	589150
159	24-Sep-25	101.60	101.60	97.60	97.80	99.00	3000	297000
160	23-Sep-25	100.00	100.00	97.50	97.50	98.79	7000	691500
161	22-Sep-25	99.00	100.00	98.40	99.80	99.68	26000	2591600
162	19-Sep-25	99.99	103.30	99.00	100.50	100.35	8000	802790
163	18-Sep-25	104.50	104.90	98.60	100.00	100.99	14000	1413900
164	17-Sep-25	101.50	103.00	101.50	101.90	102.16	5000	510800
165	16-Sep-25	104.06	104.06	102.50	102.50	103.53	9000	931730
166	15-Sep-25	105.00	107.99	104.75	106.25	106.05	5000	530240
167	12-Sep-25	105.00	105.00	102.00	104.15	104.04	4000	416150
168	11-Sep-25	109.20	109.20	103.50	105.00	107.10	14000	1499410
169	10-Sep-25	105.00	107.90	103.51	107.00	106.00	24000	2544040
170	09-Sep-25	104.00	106.00	102.00	105.60	105.03	16000	1680520
171	08-Sep-25	101.00	103.49	100.00	102.99	101.21	15000	1518190
172	05-Sep-25	98.30	101.89	97.00	100.00	97.85	31000	3033480
173	04-Sep-25	100.87	102.49	100.87	102.49	101.68	2000	203360
174	03-Sep-25	101.00	108.99	100.10	100.87	102.26	24000	2454190
175	02-Sep-25	102.90	102.90	96.00	101.54	99.23	39000	3870000
176	01-Sep-25	103.40	104.00	97.01	97.84	99.76	44000	4389530
177	29-Aug-25	104.20	104.40	96.40	99.20	100.82	13000	1310700
178	28-Aug-25	111.75	111.75	97.00	101.00	103.24	29000	2993900
179	26-Aug-25	104.95	104.95	103.10	103.10	103.72	3000	311150
180	25-Aug-25	100.90	106.90	100.90	106.25	103.08	16000	1649250
181	22-Aug-25	106.10	106.10	102.00	102.45	102.64	14000	1437000
182	21-Aug-25	101.05	105.70	101.05	104.00	103.95	10000	1039450
183	20-Aug-25	100.10	103.00	100.10	100.90	101.09	16000	1617400
184	19-Aug-25	105.00	105.00	102.00	102.00	103.59	5000	517950

Registered Valuer SFA Amninder Kaur Regd No IBBI RV 03 2021/14025

185	18-Aug-25	103.00	105.00	102.00	102.00	103.39	18000	1861000
186	14-Aug-25	105.10	105.10	102.05	105.05	103.99	17000	1767800
187	13-Aug-25	110.00	110.00	108.00	109.10	108.78	4000	435100
188	12-Aug-25	108.10	110.00	108.10	110.00	108.93	4000	435700
189	11-Aug-25	106.50	109.00	106.50	109.00	107.88	4000	431500
190	08-Aug-25	110.60	112.95	106.05	108.30	109.48	16000	1751750
191	07-Aug-25	111.50	113.80	110.00	112.00	111.67	20000	2233350
192	06-Aug-25	120.85	120.85	112.10	115.55	115.33	34000	3921100
193	05-Aug-25	117.00	120.00	115.50	119.50	118.97	23000	2736250
194	04-Aug-25	115.20	123.00	113.40	119.70	117.30	33000	3871050
195	01-Aug-25	112.30	114.00	111.60	112.30	112.57	15000	1688500
196	31-Jul-25	111.10	117.00	110.40	115.65	114.47	36000	4121000
197	30-Jul-25	116.10	117.70	112.75	114.35	114.79	29000	3329000
198	29-Jul-25	122.90	122.90	115.65	117.70	117.39	28000	3286950
199	28-Jul-25	123.00	125.50	119.20	121.70	123.15	145000	17857000
200	25-Jul-25	121.00	121.25	119.95	121.25	121.10	104000	12594500
201	24-Jul-25	110.00	115.50	107.45	115.50	113.05	56000	6330900
202	23-Jul-25	113.90	113.90	107.35	110.00	109.60	62000	6795150
203	22-Jul-25	117.00	117.00	112.60	113.00	113.76	87000	9897100
204	21-Jul-25	122.60	122.60	116.00	117.15	118.50	112000	13271550
205	18-Jul-25	124.00	126.00	117.35	120.00	120.47	182000	21925300
206	17-Jul-25	124.00	125.00	120.00	123.50	123.23	149000	18362000
207	16-Jul-25	119.00	124.95	113.05	124.95	119.63	911000	108983000

Volume of Traded Shares	**4509000**	
Total No. of Shares	**8512360**	
% of Traded Turnover to Total No. of Shares	**52.97%**	

Registered Valuer SFA ★ Regd No IBBI/RV/03/2021/14025 ★ Amninder Kaur